Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy

Kazuhiro Matsumoto, Naoya Niwa, Masayuki Hagiwara, Takeo Kosaka, Nobuyuki Tanaka, Toshikazu Takeda, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Satoshi Hara, Hiroshi Asanuma, Mototsugu Oya

Research output: Contribution to journalArticle

Abstract

Purpose: To examine the prognosis after BCR with and without salvage therapy, including radiation and/or androgen deprivation. Methods: The study population consisted of 431 patients, all of whom underwent radical prostatectomy and developed BCR (PSA > 0.2 ng/mL). According to the two risk factors [Gleason score ≥ 8 and PSA-doubling time (DT) < 6 months], we divided the patients into two groups. The high/intermediate-risk group consisted of patients with both or one risk factor. On the other hand, patients with neither factor were in the low-risk group. We set the starting point at the timing of BCR, and the endpoints were development to castration-resistant prostate cancer (CRPC) and cancer-specific death. Results: During the mean follow-up period of 8.3 years after BCR, CRPC was observed in 49 patients (11.4%), and 21 patients (4.9%) died due to prostate cancer. We first divided the 191 high/intermediate-risk patients according to the PSA level (PSA < 1.0 ng/mL, PSA 1.0–4.0, and PSA > 4.0 or no therapy) at the initiation of salvage therapy, including radiation and/or androgen deprivation. We found that delayed (PSA > 4.0 ng/mL) or no salvage therapy was significantly associated with CRPC and cancer-specific death. In the 240 low-risk patients, Kaplan–Meier curves demonstrated no significant difference in CRPC-free survival or cancer-specific survival within 10 years from the timing of BCR. Conclusions: Observation after BCR without salvage therapy or delayed administration may be an option for low-risk patients with a Gleason score ≤ 7 and PSA-DT ≥ 6 months when their life expectancy is within 10 years.

Original languageEnglish
JournalWorld Journal of Urology
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Salvage Therapy
Prostatectomy
Recurrence
Neoplasm Grading
Androgens
Radiation
Survival
Life Expectancy
Neoplasms
Observation
Population
Therapeutics

Keywords

  • Biochemical recurrence
  • Castration-resistant prostate cancer
  • Gleason score
  • PSA-doubling time
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

@article{5c3ad732dc4947bbbac85636037d4427,
title = "Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy",
abstract = "Purpose: To examine the prognosis after BCR with and without salvage therapy, including radiation and/or androgen deprivation. Methods: The study population consisted of 431 patients, all of whom underwent radical prostatectomy and developed BCR (PSA > 0.2 ng/mL). According to the two risk factors [Gleason score ≥ 8 and PSA-doubling time (DT) < 6 months], we divided the patients into two groups. The high/intermediate-risk group consisted of patients with both or one risk factor. On the other hand, patients with neither factor were in the low-risk group. We set the starting point at the timing of BCR, and the endpoints were development to castration-resistant prostate cancer (CRPC) and cancer-specific death. Results: During the mean follow-up period of 8.3 years after BCR, CRPC was observed in 49 patients (11.4{\%}), and 21 patients (4.9{\%}) died due to prostate cancer. We first divided the 191 high/intermediate-risk patients according to the PSA level (PSA < 1.0 ng/mL, PSA 1.0–4.0, and PSA > 4.0 or no therapy) at the initiation of salvage therapy, including radiation and/or androgen deprivation. We found that delayed (PSA > 4.0 ng/mL) or no salvage therapy was significantly associated with CRPC and cancer-specific death. In the 240 low-risk patients, Kaplan–Meier curves demonstrated no significant difference in CRPC-free survival or cancer-specific survival within 10 years from the timing of BCR. Conclusions: Observation after BCR without salvage therapy or delayed administration may be an option for low-risk patients with a Gleason score ≤ 7 and PSA-DT ≥ 6 months when their life expectancy is within 10 years.",
keywords = "Biochemical recurrence, Castration-resistant prostate cancer, Gleason score, PSA-doubling time, Radical prostatectomy",
author = "Kazuhiro Matsumoto and Naoya Niwa and Masayuki Hagiwara and Takeo Kosaka and Nobuyuki Tanaka and Toshikazu Takeda and Shinya Morita and Ryuichi Mizuno and Toshiaki Shinojima and Satoshi Hara and Hiroshi Asanuma and Mototsugu Oya",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00345-019-02970-w",
language = "English",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy

AU - Matsumoto, Kazuhiro

AU - Niwa, Naoya

AU - Hagiwara, Masayuki

AU - Kosaka, Takeo

AU - Tanaka, Nobuyuki

AU - Takeda, Toshikazu

AU - Morita, Shinya

AU - Mizuno, Ryuichi

AU - Shinojima, Toshiaki

AU - Hara, Satoshi

AU - Asanuma, Hiroshi

AU - Oya, Mototsugu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To examine the prognosis after BCR with and without salvage therapy, including radiation and/or androgen deprivation. Methods: The study population consisted of 431 patients, all of whom underwent radical prostatectomy and developed BCR (PSA > 0.2 ng/mL). According to the two risk factors [Gleason score ≥ 8 and PSA-doubling time (DT) < 6 months], we divided the patients into two groups. The high/intermediate-risk group consisted of patients with both or one risk factor. On the other hand, patients with neither factor were in the low-risk group. We set the starting point at the timing of BCR, and the endpoints were development to castration-resistant prostate cancer (CRPC) and cancer-specific death. Results: During the mean follow-up period of 8.3 years after BCR, CRPC was observed in 49 patients (11.4%), and 21 patients (4.9%) died due to prostate cancer. We first divided the 191 high/intermediate-risk patients according to the PSA level (PSA < 1.0 ng/mL, PSA 1.0–4.0, and PSA > 4.0 or no therapy) at the initiation of salvage therapy, including radiation and/or androgen deprivation. We found that delayed (PSA > 4.0 ng/mL) or no salvage therapy was significantly associated with CRPC and cancer-specific death. In the 240 low-risk patients, Kaplan–Meier curves demonstrated no significant difference in CRPC-free survival or cancer-specific survival within 10 years from the timing of BCR. Conclusions: Observation after BCR without salvage therapy or delayed administration may be an option for low-risk patients with a Gleason score ≤ 7 and PSA-DT ≥ 6 months when their life expectancy is within 10 years.

AB - Purpose: To examine the prognosis after BCR with and without salvage therapy, including radiation and/or androgen deprivation. Methods: The study population consisted of 431 patients, all of whom underwent radical prostatectomy and developed BCR (PSA > 0.2 ng/mL). According to the two risk factors [Gleason score ≥ 8 and PSA-doubling time (DT) < 6 months], we divided the patients into two groups. The high/intermediate-risk group consisted of patients with both or one risk factor. On the other hand, patients with neither factor were in the low-risk group. We set the starting point at the timing of BCR, and the endpoints were development to castration-resistant prostate cancer (CRPC) and cancer-specific death. Results: During the mean follow-up period of 8.3 years after BCR, CRPC was observed in 49 patients (11.4%), and 21 patients (4.9%) died due to prostate cancer. We first divided the 191 high/intermediate-risk patients according to the PSA level (PSA < 1.0 ng/mL, PSA 1.0–4.0, and PSA > 4.0 or no therapy) at the initiation of salvage therapy, including radiation and/or androgen deprivation. We found that delayed (PSA > 4.0 ng/mL) or no salvage therapy was significantly associated with CRPC and cancer-specific death. In the 240 low-risk patients, Kaplan–Meier curves demonstrated no significant difference in CRPC-free survival or cancer-specific survival within 10 years from the timing of BCR. Conclusions: Observation after BCR without salvage therapy or delayed administration may be an option for low-risk patients with a Gleason score ≤ 7 and PSA-DT ≥ 6 months when their life expectancy is within 10 years.

KW - Biochemical recurrence

KW - Castration-resistant prostate cancer

KW - Gleason score

KW - PSA-doubling time

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=85073953548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073953548&partnerID=8YFLogxK

U2 - 10.1007/s00345-019-02970-w

DO - 10.1007/s00345-019-02970-w

M3 - Article

AN - SCOPUS:85073953548

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -